Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to establish a dosage of isradipine CR that is tolerable
and demonstrates preliminary efficacy for utilization in future pivotal efficacy studies.
Phase:
Phase 2
Details
Lead Sponsor:
Northwestern University
Collaborators:
Michael J. Fox Foundation for Parkinson's Research Northwestern University Dixon Fund The Parkinson Study Group